147 related articles for article (PubMed ID: 38634916)
21. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
22. Management of patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic.
Mihaila RG
Oncol Lett; 2021 Aug; 22(2):636. PubMed ID: 34295383
[TBL] [Abstract][Full Text] [Related]
23. Can Treatment with Venetoclax for Chronic Lymphocytic Leukemia (CLL) Result In Autoimmune Hemolytic Anemia?
Abdel-Samad N; Sughayar R
Am J Case Rep; 2021 Mar; 22():e928514. PubMed ID: 33750754
[TBL] [Abstract][Full Text] [Related]
24. Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron BA.5 subvariant surge.
Bronstein Y; Levi S; Herishanu Y
Br J Haematol; 2023 Jun; 201(6):1125-1128. PubMed ID: 37042235
[TBL] [Abstract][Full Text] [Related]
25. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL.
Antic D; Milic N; Chatzikonstantinou T; Scarfò L; Otasevic V; Rajovic N; Allsup D; Alonso Cabrero A; Andres M; Baile Gonzales M; Capasso A; Collado R; Cordoba R; Cuéllar-García C; Correa JG; De Paoli L; De Paolis MR; Del Poeta G; Dimou M; Doubek M; Efstathopoulou M; El-Ashwah S; Enrico A; Espinet B; Farina L; Ferrari A; Foglietta M; Lopez-Garcia A; García-Marco JA; García-Serra R; Gentile M; Gimeno E; da Silva MG; Gutwein O; Hakobyan YK; Herishanu Y; Hernández-Rivas JÁ; Herold T; Itchaki G; Jaksic O; Janssens A; Kalashnikova OB; Kalicińska E; Kater AP; Kersting S; Koren-Michowitz M; Labrador J; Lad D; Laurenti L; Fresa A; Levin MD; Mayor Bastida C; Malerba L; Marasca R; Marchetti M; Marquet J; Mihaljevic B; Milosevic I; Mirás F; Morawska M; Motta M; Munir T; Murru R; Nunes R; Olivieri J; Pavlovsky MA; Piskunova I; Popov VM; Quaglia FM; Quaresmini G; Reda G; Rigolin GM; Shrestha A; Šimkovič M; Smirnova S; Špaček M; Sportoletti P; Stanca O; Stavroyianni N; Te Raa D; Tomic K; Tonino S; Trentin L; Van Der Spek E; van Gelder M; Varettoni M; Visentin A; Vitale C; Vukovic V; Wasik-Szczepanek E; Wróbel T; Segundo LYS; Yassin M; Coscia M; Rambaldi A; Montserrat E; Foà R; Cuneo A; Carrier M; Ghia P; Stamatopoulos K
J Hematol Oncol; 2022 Aug; 15(1):116. PubMed ID: 36028857
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection.
Diamantopoulos PT; Kontandreopoulou CN; Stafylidis C; Vlachopoulou D; Giannakopoulou N; Vardaka M; Mpouhla A; Variami E; Galanopoulos A; Pappa V; Psichogiou M; Hatzakis A; Viniou NA
Ann Hematol; 2022 Dec; 101(12):2711-2717. PubMed ID: 36271935
[TBL] [Abstract][Full Text] [Related]
27. Tumor Lysis Syndrome Caused by Unrecognized Richter's Transformation of Chronic Lymphocytic Leukemia: Treatment With Venetoclax for Suspected Disease Progression.
Chango Azanza JJ; Calle Sarmiento PM; Mathew Thomas V; Lopetegui Lia N; Kidwai N
Cureus; 2020 May; 12(5):e8145. PubMed ID: 32550064
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.
Shadman M
JAMA; 2023 Mar; 329(11):918-932. PubMed ID: 36943212
[TBL] [Abstract][Full Text] [Related]
29. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.
Chatzikonstantinou T; Kapetanakis A; Scarfò L; Karakatsoulis G; Allsup D; Cabrero AA; Andres M; Antic D; Baile M; Baliakas P; Bron D; Capasso A; Chatzileontiadou S; Cordoba R; Correa JG; Cuéllar-García C; De Paoli L; De Paolis MR; Del Poeta G; Demosthenous C; Dimou M; Donaldson D; Doubek M; Efstathopoulou M; Eichhorst B; El-Ashwah S; Enrico A; Espinet B; Farina L; Ferrari A; Foglietta M; Frederiksen H; Fürstenau M; García-Marco JA; García-Serra R; Gentile M; Gimeno E; Glenthøj A; Gomes da Silva M; Gutwein O; Hakobyan YK; Herishanu Y; Hernández-Rivas JÁ; Herold T; Innocenti I; Itchaki G; Jaksic O; Janssens A; Kalashnikova ОB; Kalicińska E; Karlsson LK; Kater AP; Kersting S; Labrador J; Lad D; Laurenti L; Levin MD; Lista E; Lopez-Garcia A; Malerba L; Marasca R; Marchetti M; Marquet J; Mattsson M; Mauro FR; Milosevic I; Mirás F; Morawska M; Motta M; Munir T; Murru R; Niemann CU; Rodrigues RN; Olivieri J; Orsucci L; Papaioannou M; Pavlovsky MA; Piskunova I; Popov VM; Quaglia FM; Quaresmini G; Qvist K; Reda G; Rigolin GM; Ruchlemer R; Saghumyan G; Shrestha A; Šimkovič M; Špaček M; Sportoletti P; Stanca O; Stavroyianni N; Tadmor T; Te Raa D; Tonino SH; Trentin L; Van Der Spek E; van Gelder M; van Kampen R; Varettoni M; Visentin A; Vitale C; Wasik-Szczepanek E; Wróbel T; San Segundo LY; Yassin M; Coscia M; Rambaldi A; Montserrat E; Foà R; Cuneo A; Stamatopoulos K; Ghia P
Leukemia; 2021 Dec; 35(12):3444-3454. PubMed ID: 34725454
[TBL] [Abstract][Full Text] [Related]
30. Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia.
Waggoner M; Katsetos J; Thomas E; Galinsky I; Fox H
J Adv Pract Oncol; 2022 May; 13(4):400-415. PubMed ID: 35755897
[TBL] [Abstract][Full Text] [Related]
31. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
[TBL] [Abstract][Full Text] [Related]
32. Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
Hillmen P; Rawstron AC; Brock K; Muñoz-Vicente S; Yates FJ; Bishop R; Boucher R; MacDonald D; Fegan C; McCaig A; Schuh A; Pettitt A; Gribben JG; Patten PEM; Devereux S; Bloor A; Fox CP; Forconi F; Munir T
J Clin Oncol; 2019 Oct; 37(30):2722-2729. PubMed ID: 31295041
[TBL] [Abstract][Full Text] [Related]
33. Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia.
Sarapura Martinez VJ; Buonincontro B; Cassarino C; Bernatowiez J; Colado A; Cordini G; Custidiano MDR; Mahuad C; Pavlovsky MA; Bezares RF; Favale NO; Vermeulen M; Borge M; Giordano M; Gamberale R
Front Oncol; 2023; 13():1143881. PubMed ID: 37020867
[TBL] [Abstract][Full Text] [Related]
34. Landscape of
Kotmayer L; László T; Mikala G; Kiss R; Lévay L; Hegyi LL; Gróf S; Nagy T; Barna G; Farkas P; Weisinger J; Nagy Z; Balogh A; Masszi T; Demeter J; Sulák A; Kohl Z; Alizadeh H; Egyed M; Pettendi P; Gergely L; Plander M; Pauker Z; Masszi A; Matolcsy A; Szász R; Bödör C; Alpár D
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982875
[TBL] [Abstract][Full Text] [Related]
35. Venetoclax alone or in combination with other regimens treatment achieve deep and sustained remission of relapsed/refractory chronic lymphocytic leukemia: a meta-analysis.
Tang X; Zou W; Peng P; Bai Y
Clin Exp Med; 2022 May; 22(2):161-171. PubMed ID: 34224006
[TBL] [Abstract][Full Text] [Related]
36. The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.
Visentin A; Chatzikonstantinou T; Scarfò L; Kapetanakis A; Demosthenous C; Karakatsoulis G; Minga E; Chamou D; Allsup D; Cabrero AA; Andres M; Antic D; Baile M; Baliakas P; Besikli-Dimou S; Bron D; Chatzileontiadou S; Cordoba R; Correa JG; Cuéllar-García C; De Paoli L; De Paolis MR; Delgado J; Dimou M; Donaldson D; Catherwood M; Doubek M; Efstathopoulou M; Eichhorst B; Elashwah S; Enrico A; Espinet B; Farina L; Ferrari A; Foglietta M; Frederiksen H; Fürstenau M; García-Marco JA; García-Serra R; Collado R; Gentile M; Gimeno E; Glenthøj A; da Silva MG; Hakobyan YK; Herishanu Y; Hernández-Rivas JÁ; Herold T; Innocenti I; Itchaki G; Jaksic O; Janssens A; Kalashnikova ОB; Kalicińska E; Kater AP; Kersting S; Labrador J; Lad D; Laurenti L; Levin MD; Lista E; Lopez-Garcia A; Malerba L; Marasca R; Marchetti M; Marquet J; Mattsson M; Mauro FR; Morawska M; Motta M; Munir T; Murru R; Niemann CU; Rodrigues RN; Olivieri J; Orsucci L; Papaioannou M; Pavlovsky MA; Piskunova I; Popov VM; Quaglia FM; Quaresmini G; Qvist K; Rigolin GM; Ruchlemer R; Šimkovič M; Špaček M; Sportoletti P; Stanca O; Tadmor T; Capasso A; Del Poeta G; Gutwein O; Karlsson LK; Milosevic I; Mirás F; Reda G; Saghumyan G; Shrestha A; Te Raa D; Tonino SH; Van Der Spek E; van Gelder M; van Kampen R; Wasik-Szczepanek E; Wróbel T; Segundo LYS; Yassin M; Pocali B; Vandenberghe E; Iyengar S; Varettoni M; Vitale C; Coscia M; Rambaldi A; Montserrat E; Cuneo A; Stavroyianni N; Trentin L; Stamatopoulos K; Ghia P
Am J Hematol; 2023 Dec; 98(12):1856-1868. PubMed ID: 37772428
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the novel therapeutic anti-CCR7 antibody CAP-100 as an add-on therapy in chronic lymphocytic leukemia patients receiving venetoclax.
Mateu-Albero T; Marcos-Jimenez A; Delgado-Wicke P; Terrón F; Loscertales J; López-Matencio JMS; Muñoz-Calleja C; Cuesta-Mateos C
Hematol Oncol; 2023 Dec; 41(5):869-876. PubMed ID: 37545392
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
Herishanu Y; Avivi I; Aharon A; Shefer G; Levi S; Bronstein Y; Morales M; Ziv T; Shorer Arbel Y; Scarfò L; Joffe E; Perry C; Ghia P
Blood; 2021 Jun; 137(23):3165-3173. PubMed ID: 33861303
[TBL] [Abstract][Full Text] [Related]
39. The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Schieber M; Ma S
Blood Lymphat Cancer; 2019; 9():9-17. PubMed ID: 32009829
[TBL] [Abstract][Full Text] [Related]
40. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
